--- title: "Thermo Fisher Scientific Inc Stock (TMO) Moved Down by 3.53% on Mar 12: What Investors Need To Know" type: "News" locale: "en" url: "https://longbridge.com/en/news/278921873.md" description: "Thermo Fisher Scientific Inc (TMO) saw a 3.53% decline in stock price, influenced by an upcoming ex-dividend date and insider selling by CEO Marc N. Casper. Despite strong Q4 earnings, analysts maintain a positive outlook, but recent market trends indicate broader weakness. The company ranks 2nd in annual revenue within the Healthcare Services & Equipment sector, with a net profit of $6.70B. Analysts have rated TMO as a Buy, with a price target averaging $662.47. Risks include lower-than-expected financial guidance and sector-specific challenges." datetime: "2026-03-12T17:19:16.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278921873.md) - [en](https://longbridge.com/en/news/278921873.md) - [zh-HK](https://longbridge.com/zh-HK/news/278921873.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/278921873.md) | [繁體中文](https://longbridge.com/zh-HK/news/278921873.md) # Thermo Fisher Scientific Inc Stock (TMO) Moved Down by 3.53% on Mar 12: What Investors Need To Know Thermo Fisher Scientific Inc (TMO) moved down by 3.53%. The Healthcare Services & Equipment sector is down by 1.53%. The company underperformed the industry. Top 3 stocks by turnover in the sector: Unitedhealth Group Inc (UNH) down 2.04%; Hims & Hers Health Inc (HIMS) down 2.94%; Stryker Corp (SYK) down 2.14%. ## What is driving Thermo Fisher Scientific Inc (TMO)’s stock price down today? Thermo Fisher Scientific (TMO) experienced a decline today, primarily influenced by the impending ex-dividend date and recent insider selling activity. Shares often adjust downwards on or just before the ex-dividend date, as new buyers will not qualify for the upcoming dividend payment. The company's ex-dividend date for its quarterly dividend of $0.47 per share is set for tomorrow, March 13, 2026. This forward-looking adjustment in share price is a common market dynamic. Adding to the downward pressure, the firm's CEO, Marc N. Casper, engaged in selling activity, offloading a notable number of shares on March 11, 2026. While such sales can be for various reasons, including personal financial planning, they are often perceived by the market as a negative signal, contributing to investor caution and potentially influencing short-term share price movements. These company-specific factors appear to be the dominant drivers behind today's significant intraday volatility. While recent Q4 and full-year 2025 earnings reported on January 29, 2026, were strong and exceeded analyst estimates, and analysts generally maintain a positive outlook with "Moderate Buy" or "Strong Buy" ratings, these earlier positive indicators likely have already been factored into the stock's valuation. Furthermore, a recent market assessment on March 11, 2026, indicated that the stock had already shown a several-day and monthly decline, suggesting a broader weakness in the period leading up to today's movement. ## Technical Analysis of Thermo Fisher Scientific Inc (TMO) Technically, Thermo Fisher Scientific Inc (TMO) shows a MACD (12,26,9) value of \[-17.13\], indicating a neutral signal. The RSI at 33.03 suggests neutral condition and the Williams %R at -84.95 suggests oversold condition. Please monitor closely. ## Fundamental Analysis of Thermo Fisher Scientific Inc (TMO) Thermo Fisher Scientific Inc (TMO) is in the Healthcare Services & Equipment industry. Its latest annual revenue is $44.56B, ranking 2 in the industry. The net profit is $6.70B, ranking 1 in the industry. Company Profile Over the past month, multiple analysts have rated the company as Buy, with an average price target of $662.47, a high of $750.00, and a low of $595.00. ## More details about Thermo Fisher Scientific Inc (TMO) Company Specific Risks: - Lower-than-expected 2026 financial guidance, including conservative organic growth projections for Q1 and the full year, with anticipated first-quarter earnings per share falling significantly below analyst expectations. - Persistent margin compression as evidenced by a 150 basis point decline in gross margin during Q4 2025, which contributed to negative stock reaction despite an earnings beat. - Ongoing vulnerability to sector-specific headwinds such as lower exposure to the resilient bioprocessing sector, heightened sensitivity to NIH funding reductions, and delays in pharmaceutical projects affecting its contract research organization (CRO) business, leading to underperformance against peers. Find out more ### Related Stocks - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [SPDR® S&P Health Care Equipment ETF (XHE.US)](https://longbridge.com/en/quote/XHE.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) - [iShares US Medical Devices ETF (IHI.US)](https://longbridge.com/en/quote/IHI.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [Thermo Fisher Scientific Inc. (TMO.US)](https://longbridge.com/en/quote/TMO.US.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Direxion Daily S&P Biotech Bull 3X ETF (LABU.US)](https://longbridge.com/en/quote/LABU.US.md) ## Related News & Research - [Thermo Fisher Scientific Introduces Gibco Cts Compleo Fill and Finish System](https://longbridge.com/en/news/281553253.md) - [USA Antimicrobial Susceptibility Testing Market to Reach USD 1.8 Billion by 2035, Driven by Rising Antimicrobial Resistance and Diagnostic Innovation](https://longbridge.com/en/news/281334643.md) - [Here's How Much $100 Invested In Thermo Fisher Scientific 15 Years Ago Would Be Worth Today](https://longbridge.com/en/news/278969127.md) - [EU Commission OKs Thermo Fisher Purchase of Clario](https://longbridge.com/en/news/279937391.md) - [11:05 ETLabCentral's 2025 Impact Report Shows Continued Progress for the Life Sciences Industry](https://longbridge.com/en/news/280496520.md)